RenalGuard features in high-risk live case at CTO Fundamentals Course

221

RenalGuard Solutions has been featured in a high-risk coronary chronic total occlusion (CTO) live case presentation at the recent CTO Fundamentals Course, June 3, 2016, VU University Medical Center, Amsterdam, The Netherlands.

The case, performed by Paul Knaapen and Alex Nap, focused on a cardiac patient with stage four chronic kidney disease undergoing a chronic total occlusion procedure while being treated with RenalGuard. Despite receiving a large volume of contrast as part of the procedure, the patient emerged with intact renal function.

“This case highlights the importance of protecting the kidney in high-risk chronic total occlusion patients,” says Andrew Halpert, president, RenalGuard Solutions. “The patient in the featured case presented with both severe cardiac disease and renal disease. The innovative techniques used during the case allowed the physicians to address a very complicated cardiac lesion, but required a large volume of contrast which can be toxic to the kidney. By using RenalGuard, they were able to treat the patient’s cardiac disease while providing a high level of kidney protection.”

RenalGuard measures a patient’s urine output and automatically infuses hydration fluid based on that urine output. The system is designed to induce high urine rates, which have been shown to protect the kidney from a range of insults. A number of clinical studies have demonstrated RenalGuard’s ability to protect patients from acute kidney infection following catheterisation procedures when compared to the standard of care, including: MYTHOS, which found RenalGuard to be superior to overnight hydration; REMEDIAL II, which found RenalGuard to be superior to sodium bicarbonate hydration; Protect-TAVI, which reported a significant reduction in post-procedural acute kidney injury (AKI) following transcatheter aortic valve replacement (TAVR) when using RenalGuard during the procedure, compared to standard therapy; and AKIGUARD, which showed significant improvement in long-term outcomes when using RenalGuard vs. standard therapy.